"Antibodies, Neutralizing" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Antibodies that reduce or abolish some biological activity of a soluble antigen or infectious agent, usually a virus.
| Descriptor ID |
D057134
|
| MeSH Number(s) |
D12.776.124.486.485.114.244 D12.776.124.790.651.114.244 D12.776.377.715.548.114.244
|
| Concept/Terms |
|
Below are MeSH descriptors whose meaning is more general than "Antibodies, Neutralizing".
Below are MeSH descriptors whose meaning is more specific than "Antibodies, Neutralizing".
This graph shows the total number of publications written about "Antibodies, Neutralizing" by people in this website by year, and whether "Antibodies, Neutralizing" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2021 | 1 | 0 | 1 |
| 2022 | 0 | 2 | 2 |
| 2024 | 0 | 1 | 1 |
| 2025 | 0 | 2 | 2 |
| 2026 | 0 | 2 | 2 |
To return to the timeline,
click here.
Below are the most recent publications written about "Antibodies, Neutralizing" by people in Profiles.
-
Immune correlates of risk for SARS-CoV-2 infection in children: a prospective, community-based cohort study. Nat Commun. 2026 Jul 18; 17(1).
-
Durability of the Mumps Antibody Response After the Third Dose of MMR Vaccine. J Infect Dis. 2026 Feb 18; 233(2):e383-e391.
-
Correlates of risk of respiratory syncytial virus disease: a prospective cohort study. Nat Commun. 2025 Sep 26; 16(1):8490.
-
Safety profile of self-amplifying mRNA SARS-CoV-2 vaccine ARCT-154 in adults: a pooled phase 1/2/3 randomized clinical study. Expert Rev Vaccines. 2025 Dec; 24(1):299-312.
-
Ipsilateral and contralateral coadministration of influenza and COVID-19 vaccines produce similar antibody responses. EBioMedicine. 2024 May; 103:105103.
-
BNT162b2 vaccine effectiveness against SARS-CoV-2 omicron BA.4 and BA.5. Lancet Infect Dis. 2022 12; 22(12):1663-1665.
-
Rapid decline in vaccine-boosted neutralizing antibodies against SARS-CoV-2 Omicron variant. Cell Rep Med. 2022 Jul 19; 3(7):100679.
-
Protection with a Third Dose of mRNA Vaccine against SARS-CoV-2 Variants in Frontline Workers. N Engl J Med. 2022 05 12; 386(19):1855-1857.
-
Safety, Immunogenicity, and Efficacy of the BNT162b2 Covid-19 Vaccine in Adolescents. N Engl J Med. 2021 07 15; 385(3):239-250.
-
Antibody Persistence through 6 Months after the Second Dose of mRNA-1273 Vaccine for Covid-19. N Engl J Med. 2021 06 10; 384(23):2259-2261.